Work

A Phase Ib/II Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib Plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

Year: 2018

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2018-99-117773

Authors: Irene M. Ghobrial, Chia-Jen Liu, Raymond P. Perez, Paul Richardson, Kenneth C. Anderson, Jacob Laubach, Patrick Henrick, Alexandra Savell, Kaitlen Reyes, Kalvis Hornburg, Stacey Chuma, Peter Sabbatini, Pamela S. Becker

Institutions: Harvard University, Dana-Farber Cancer Institute, The University of Kansas Cancer Center, Dana-Farber/Harvard Cancer Center, Bristol-Myers Squibb (United States), University of Washington, Fred Hutch Cancer Center

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1452517274

Cites:

Cited by: 11

Related to: 10